Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mead Johnson Appealing NAD Enfamil Performance Claim Decision To NARB

This article was originally published in The Tan Sheet

Executive Summary

Mead Johnson Advanced Formula Enfamil With Iron nutrient content, value and origin ad claims are supported with a few minor stipulations, the National Advertising Division of the Council of Better Business Bureaus concludes in the February NAD Case Reports.

You may also be interested in...



Nestle Carnation Good Start Infant Formula "Comfort Proteins" Unique - NAD

The hydrolyzed whey "Comfort Proteins" in Nestle's Carnation Good Start infant formulas are unique to the product and do not mislead consumers, the National Advertising Division of the Council of Better Business Bureaus rules in its November NAD Case Reports.

Nestle Carnation Good Start Infant Formula "Comfort Proteins" Unique - NAD

The hydrolyzed whey "Comfort Proteins" in Nestle's Carnation Good Start infant formulas are unique to the product and do not mislead consumers, the National Advertising Division of the Council of Better Business Bureaus rules in its November NAD Case Reports.

Nestle Carnation Good Start Infant Formula "Comfort Proteins" Unique - NAD

The hydrolyzed whey "Comfort Proteins" in Nestle's Carnation Good Start infant formulas are unique to the product and do not mislead consumers, the National Advertising Division of the Council of Better Business Bureaus rules in its November NAD Case Reports.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091099

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel